awmsg logo



ciprofloxacin (Cetraxal®)


Reference No. 1343

Publication date:
25/07/2018


Appraisal information

ciprofloxacin (Cetraxal®) 2 mg/ml ear drops


Company: Aspire Pharma Ltd
BNF category: Ear, nose and oropharynx
NMG meeting date: 16/05/2018
AWMSG meeting date: 18/07/2018
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1218
Ratification by Welsh Government: 23/07/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Ciprofloxacin (Cetraxal®) is recommended as an option for use within NHS Wales for the treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane, caused by ciprofloxacin susceptible microorganisms.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download